Next Century Growth Investors LLC Purchases 31,089 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Key Points

• Next Century Growth Investors LLC increased its ownership in Mirum Pharmaceuticals by 18.9%, acquiring an additional 31,089 shares, bringing their total to approximately 195,341 shares valued at $8.8 million.
• Insider activity included significant sales, with CEO Christopher Peetz selling 40,000 shares for $2.48 million, indicating a 22.39% decrease in his ownership.
• Mirum Pharmaceuticals reported a revenue of $127.79 million for the quarter, a 64.1% increase compared to the previous year, and beat earnings estimates by $0.19.

Next Century Growth Investors LLC boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 18.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 195,341 shares of the company's stock after purchasing an additional 31,089 shares during the period. Next Century Growth Investors LLC owned approximately 0.39% of Mirum Pharmaceuticals worth $8,800,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of MIRM. CWM LLC lifted its stake in shares of Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company's stock valued at $27,000 after buying an additional 428 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $35,000. Comerica Bank grew its holdings in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after purchasing an additional 278 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $42,000. Finally, KBC Group NV purchased a new stake in Mirum Pharmaceuticals in the 1st quarter valued at about $89,000.

Insider Activity

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $58.00, for a total value of $580,000.00. Following the completion of the sale, the senior vice president owned 2,426 shares of the company's stock, valued at $140,708. This trade represents a 80.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Peetz sold 40,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $62.00, for a total value of $2,480,000.00. Following the transaction, the chief executive officer owned 138,641 shares of the company's stock, valued at approximately $8,595,742. This trade represents a 22.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,041 shares of company stock worth $5,320,624 over the last quarter. Insiders own 14.36% of the company's stock.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $74.65 on Thursday. Mirum Pharmaceuticals, Inc. has a 1-year low of $36.86 and a 1-year high of $75.41. The stock has a market cap of $3.75 billion, a PE ratio of -61.69 and a beta of 0.94. The firm has a 50-day simple moving average of $56.19 and a two-hundred day simple moving average of $48.90. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.13 and a quick ratio of 2.97.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.19. The business had revenue of $127.79 million during the quarter, compared to the consensus estimate of $107.91 million. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The company's revenue was up 64.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.52) EPS. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MIRM. Wall Street Zen cut shares of Mirum Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday. HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 7th. Raymond James Financial reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a report on Thursday, August 7th. Stifel Nicolaus set a $89.00 price objective on shares of Mirum Pharmaceuticals and gave the company a "buy" rating in a report on Monday, August 11th. Finally, Evercore ISI increased their price objective on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $74.13.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.